Combioxin is a Swiss-based biotechnology company dedicated to the development of first-in-class life-saving drugs for severe infections.
The company entered into worldwide licensing agreement with Eagle Pharmaceuticals for the commercial rights to its pipeline.
FDA grants Qualified Infectious Disease Product (QIDP) and Fast-Track Designations for CAL02
June 13, 2023
Pneumonia is the most common infection requiring hospitalization and admission to the intensive care unit (ICU), and is the third most common cause of death globally with 2.4 million deaths per year
There are >300 million cases per year
2’400 / day
CHILDREN < 5 YEARS DYING
OF PNEUMONIA
2.4 million
DEATHS CAUSED ANNUALLY
BY PNEUMONIA
Up to 50%
MORTALITY RATES OF
SEVERE PNEUMONIA
FOUNDING MEMBERS
Samareh Azeredo da Silveira
Managing Director
Frédéric Lajaunias
Managing Director